Transcatheter Cardiovascular Therapeutics industry round-up August 2007

FDA happenings: First “upstream” embolic protection system gains clearance; Cryoablation system deemed approvable with conditions; Shelhigh stops distribution; and more

Reimbursement issues: Medicare members indecisive on paying for renal artery stenting

Around the industry: Kensey Nash terminates its embolic protection line; DES sales continue to decline; Endeavor meets primary endpoint in pivotal trial; and more

Proceedings of TCT 4, 18-20 (2007).
view PDF
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: